FDA Alerts

The FDA has approved Spiriva Respimat for long-term, once-daily maintenance treatment of asthma in individuals aged 6 and older.

The FDA approved the injection Siliq (brodalumab) to treat adults with moderate to severe plaque psoriasis.

The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of patients aged 5 years and older with Duchenne muscular dystrophy.

The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.

The FDA has expanded the use of Opdivo (nivolumab) for the treatment of patients with urothelial carcinoma, the most common form of bladder cancer.

The FDA approved Symbicort Inhalation Aerosol 80/4.5 for the treatment for the treatment of asthma in pediatric patients aged 6 to 12 years.

The FDA has approved AirDuo RespiClick and ArmonAir RespiClick for the treatment of adolescent and adult patients with asthma.

The FDA has approved Trulance (plecanatide) for the treatment of chronic idiopathic constipation in adults.

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.

The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.